Research programme: spinal stem cell therapeutics - DiscGenics

Drug Profile

Research programme: spinal stem cell therapeutics - DiscGenics

Alternative Names: Allogeneic therapeutic progenitor cells - DiscGenics; Discogenic cells; Discospheres™; IDCT - DiscGenics; Injectable discogenic cell therapy - DiscGenics

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DiscGenics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Intervertebral disc degeneration

Most Recent Events

  • 03 Oct 2017 DiscGenics plans a clinical trial for Intervertebral disc degeneration in USA in the fourth quarter of 2017
  • 03 Oct 2017 DiscGenics Receives allowance of an IND application from FDA for initiation of a clinical trial of IDCT in Intervertebral disc degeneration in USA
  • 03 Nov 2016 DiscGenics receives patent allowance for Discogenic Cell technology in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top